Question follow-through · 42185
Pharmacy: Finance
To ask the Secretary of State for Health and Social Care, if he will made an assessment of the potential merits of increasing the length of funding periods of pharmacies.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 27 Mar 2025
- Target answer date
- 1 Apr 2025
- Answer
- 2 Apr 2025 · 6 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
More questions by this MP on Health and care
- NHS England · 31 Mar 2025
- NHS: Databases · 31 Mar 2025
- Dementia: Research · 1 Apr 2025
- Dementia: Clinical Trials · 1 Apr 2025
- Pharmacy · 17 Apr 2025
Shared topic keywords suggest a connection; they do not establish a follow-up.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
27 Mar 2025
Question tabled
To ask the Secretary of State for Health and Social Care, if he will made an assessment of the potential merits of increasing the length of funding periods of pharmacies.
1 Apr 2025
Target answer date
Date supplied by the official written-questions record.
2 Apr 2025
Answer published
We have now concluded the consultation on funding for 2024/25 and 2025/26, and have agreed with Community Pharmacy England to increase the community pharmacy contractual framework to £3.073 billion. This deal represents the largest uplift in funding of an...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
NHS England
31 Mar 2025 · To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of closing NHS England on the (a) timeline for the production of the NHS 10-year plan and (b) publication date of that plan.
NHS: Databases
31 Mar 2025 · To ask the Secretary of State for Health and Social Care, if he will consider the final costs and benefits statement for programmes delivered under the National Programme of Technology, published on 6 June 2013, in his plans for (a) an NHS Federated Data
Dementia: Research
1 Apr 2025 · To ask the Secretary of State for Health and Social Care, how much funding was allocated to dementia research by (a) the National Institute for Health and Care Research, (b) UK Research and Innovation and (c) other public bodies in each of the last five y
Dementia: Clinical Trials
1 Apr 2025 · To ask the Secretary of State for Health and Social Care, how many phase (a) one, (b) two and (c) three dementia clinical trials there have been in the UK in each of the last ten years; and how many participants were recruited for each of those trials.
Pharmacy
17 Apr 2025 · To ask the Secretary of State for Health and Social Care, when he plans to publish the report on economic review into community pharmacy.
Spinal Muscular Atrophy: Babies
24 Apr 2025 · To ask the Secretary of State for Health and Social Care, what recent discussions he has had with the UK National Screening Committee on timelines for implementing in-service evaluation of newborn screening for spinal muscular atrophy.
Spinal Muscular Atrophy: Babies
24 Apr 2025 · To ask the Secretary of State for Health and Social Care, what information the UK National Screening Committee has provided on the (a) format, (b) scale and (c) duration of the upcoming in-service evaluation of newborn screening for Spinal Muscular Atroph
Spinal Muscular Atrophy: Babies
24 Apr 2025 · To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of launching newborn screening for Spinal Muscular Atrophy alongside the upcoming launch of newborn screening for severe combined immunodeficienc
Hormone Replacement Therapy
7 May 2025 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 March 2025 to Question 35541 on Hormone Replacement Therapy, what discussions he has had with the Medicines and Healthcare products Regulatory Agency on the adequacy of
Hormone Replacement Therapy
7 May 2025 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 March 2025 to Question 35541 on Hormone Replacement Therapy, what discussions he has had with the Medicines and Healthcare products Regulatory Agency on the adequacy of
Hormone Replacement Therapy
7 May 2025 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 March 2025 to Question 35541 on Hormone Replacement Therapy, what discussions he has had with the Medicines and Healthcare products Regulatory Agency on encouraging manu
Spinal Muscular Atrophy: Babies
12 May 2025 · To ask the Secretary of State for Health and Social Care, what information has been provided to him on the reason for the delay on publication of the National Institute for Health and Care Research research brief that will inform the UK National Screening